BIIB•benzinga•
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
Summary
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga